In patients with type 2 diabetes
with high CV risk
with high CV risk
CV DEATH
HAS A
NEW OPPONENT
Jardiance® (empagliflozin) is the only type 2 diabetes pill proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease
Efficacy
PC-TH-100297
Production date: Sep 2019
Production date: Sep 2019
What is JARDIANCE® (empagliflozin)?
JARDIANCE® (empagliflozin) tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
JARDIANCE® (empagliflozin) tablets are indicated to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
JARDIANCE® (empagliflozin) tablets are indicated to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Important safety information
What is the most important information I should know about JARDIANCE® (empagliflozin)
Who should not use JARDIANCE® (empagliflozin)
For more information, please see Prescribing Information
- Dehydration
- Ketoacidosis
- Urinary tract infections
- Genital tract infections
Who should not use JARDIANCE® (empagliflozin)
- Type 1 DM
- Patients with persistent eGFR<45 ml/min/1.73 m2
For more information, please see Prescribing Information